|
Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
RECRUITINGSponsored by Indiana University
Actively Recruiting
SponsorIndiana University
Started2026-03-24
Est. completion2028-04
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07676565
Summary
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Adults ≥18 years of age * Clinical diagnosis of T1D * GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week * Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study * Willing and able to provide informed consent Exclusion Criteria: * No exclusion criteria other than those not meeting inclusion criteria above
Conditions2
DiabetesType 1 Diabetes
Locations7 sites
Hoag Memorial Hospital
Northwestern University
Maine Health Research Institute
Portland, Maine, 04102
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorIndiana University
Started2026-03-24
Est. completion2028-04
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07676565